Viral hepatitis C vaccine candidate for seniors: The CDC
A vaccine candidate developed by the U.S. Centers for Disease Control and Prevention is expected to be available for seniors within months.
The new vaccine candidate, called HS-2, was developed by a team of scientists led by Dr. Mark C. Rodebaugh, who previously led research on a vaccine for older adults, the CDC announced Friday.
The vaccine candidate is based on a virus that can infect the skin of healthy adults, but it is not the first vaccine candidate to be developed for seniors.
Earlier this year, a new vaccine for seniors was approved by the Food and Drug Administration for the treatment of the virus.
The FDA had previously approved the first HS-1 vaccine for the prevention of colds and influenza, which is now available for all Americans, according to the CDC.
The virus can be passed from an infected person to another.
The first vaccine, developed in the early 2000s, was effective against HS-3 and HS-4, and the HS-5 vaccine is not expected to offer any protection against HSs-6 and HSs.
But the HSs is a very aggressive virus, so there is a need for more effective vaccines, said Dr. David A. Cohen, the senior vice president of vaccine development at AstraZeneca, a biotech company based in New York City.
The CDC is working with Astra to develop a new HS-8 vaccine for adults who have already received two HS vaccines.
The U.K. also plans to use HS-9 for adults and children, and a vaccine is also in the development stage for people in the U-40 age group.
This vaccine would be administered in the form of a gel, and would have a longer half-life than the HS vaccine.
“This vaccine has a longer life span, which will help us deliver more than 100 times the dose to people who need it,” Cohen said.
He added that Astra’s HS-10 vaccine would also have a shorter half-lifetime than HS-11, and that the company hopes to develop the vaccine by the end of the year.
The HS vaccine candidate was developed to be a candidate for HS-6, which has been resistant to all HS vaccines so far, said Aya H. Al-Hussain, an assistant professor at the Johns Hopkins Bloomberg School of Public Health and a senior research associate at the institute.
Al Hussain said the new vaccine is an evolution of a vaccine developed in 2007 by researchers at the University of Washington.
The research team’s work included identifying and isolating strains of HS-7 and HS4, which have not been tested against HSV-1.
The study was published online Jan. 27 in the journal PLoS Pathogens.
Al Haussain was not involved in the study, but he said the findings provide “some new insights into how to develop an effective HS vaccine.”
In the past, HS vaccines were developed by large pharmaceutical companies, but they are expensive, time-consuming and are difficult to market.
Al Haytham, a senior scientist at the UMC’s Center for the Study of Genomics and Emerging Infectious Diseases, said he hopes HS-13, which was developed with the same approach, will be more cost-effective and safer than HS vaccines for adults.
HS vaccines are being developed at the National Institutes of Health in a partnership with Novartis.
“We’re hopeful the HS2 vaccine will be successful, but that the vaccine is more efficient, which means that it will be better for the elderly and people with pre-existing conditions,” Al Haydam said.
The National Institutes for Health is a federal agency that develops and delivers biomedical research, development and medical education grants.
For more on the HS vaccines, visit the U of M website.
Copyright © 2017 The Associated Press.
All rights reserved.
This material may not be published, broadcast, rewritten or redistributed without permission.
Get local news delivered to your inbox!